Entacapone in the management of Parkinson’s disease

Author： Waters Cheryl   Henchcliffe Claire  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.3, Iss.7, 2002-07, pp. : 957-963

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Entacapone, a catechol-O-methyltransferase inhibitor for treating Parkinson’s disease: review and current status

By Gottwald M.D.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 4, 1999-04 ,pp. : 453-462

Informa Healthcare

Access to resources Recommend Favorite

Psychotic symptoms in Parkinson’s disease: pathophysiology and management

By Bosboom JLW   Wolters ECh  

Expert Opinion on Drug Safety, Vol. 3, Iss. 3, 2004-05 ,pp. : 209-220

Informa Healthcare

Access to resources Recommend Favorite

Levodopa-Induced Response Fluctuations in Patients with Parkinson’s Disease: Strategies for Management

By van Laar T.  

CNS Drugs, Vol. 17, Iss. 7, 2003-01 ,pp. : 475-489

Adis International

Access to resources Recommend Favorite

Entacapone adjunctive therapy clear choice in Parkinson's disease

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 297, 2001-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Entacapone: A Review of its Use in Parkinson's Disease

By Holm K.J.   Spencer C.M.  

Drugs, Vol. 58, Iss. 1, 1999-07 ,pp. : 159-177

Adis International

Access to resources Recommend Favorite